Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Neurological disorders

- PMLiVE

Alzheimer’s Association report highlights need to improve patient-physician communication

Both individuals and primary care physicians reported a reluctance to address cognitive concerns

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration

US veterans in the early stages of the disease who meet VHA criteria will be eligible for coverage

- PMLiVE

FDA grants priority review for traditional approval of Biogen and Eisai’s Alzheimer’s drug

Leqembi was granted accelerated approval in the US earlier this year

Biogen Idec building

Safety-related change to label for Biogen’s Alzheimer’s drug Aduhelm approved by FDA

Larger areas of bleeding on the brain have been reported in some patients taking the drug

- PMLiVE

Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval

The FDA said there was not enough trial data from patients who were treated for at least a year

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug receives FDA accelerated approval

An application has also been submitted for US approval under the traditional pathway

- PMLiVE

BioXcel Therapeutics doses first patient in phase 3 Alzheimer’s-associated agitation trial

Around 100 million agitation episodes are reported in the US each year in Alzheimer’s patients

- PMLiVE

Eisai and Washington University to develop neurodegenerative disease therapies

Alzheimer’s will be a central focus for the new drug discovery collaboration

- PMLiVE

Lilly’s donanemab shows promise in early symptomatic Alzheimer’s comparator study

Brain amyloid clearance was achieved in 37.9% of patients treated with the investigational antibody

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug shown to slow memory decline in confirmatory study

The findings have been described as a ‘major step forward’ for dementia research

- PMLiVE

New study finds signs of dementia could be detected nine years before diagnosis

Impairment was observed in several areas across a range of dementia-related diseases

- PMLiVE

New study links omega-3 intake in midlife to reduced dementia risk

Over 2,000 people who did not have dementia or stroke took part in the study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links